@JackPrescottX JackPrescottX

Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY. · Analyst brief as of 2026-08-16.

The author owns ABCL and PLTR, with attention overwhelmingly concentrated on ABCL after ABCL635 exceeded clinical expectations. Their distinctive read is that ABCL’s dilutive raise finances a wholly owned blockbuster opportunity, while PLTR skepticism overlooks strategic defense and industrial demand. Late-week disclosures retained both positions and introduced only a conditional future ABCL trim threshold, not an executed reduction.

ABCL conviction was reinforced by Phase 2 results, platform-validation commentary, analyst target increases, and an insider purchase; the author treated the subsequent financing as strategically constructive despite dilution. PLTR remained a consistently held secondary position, with no executed trim, exit, or directional flip; the late-week ABCL update introduced only a conditional future trim threshold. ABCL represents the clear concentration and pump-risk concern.

Alignment separates skin-in-the-game from commentary: ✓ = the author discloses a position consistent with their talk; “call (no pos)” = directional call without a disclosed position; “commentary” = opinion only.

Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.